Cancer-Associated Thrombosis, Arterial and Venous Thromboembolism
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 5
Special Issue Editor
Interests: monitoring of new oral anticoagulant drugs; Stevens Johnson syndrome/toxic epidermal necrolysis; COVID-19-associated thrombosis; pulmonary embolism; personalized medicine; cancer-associated thrombosis; pharmacogenomics and pharmacovigilance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue on “Cancer-Associated Thrombosis, Arterial and Venous Thromboembolism” is dedicated to three scientists: Jean-Baptiste Bouillaud, a prominent French physician who first described the association between cancer and thrombosis in 1823; Armand Trousseau (1801–1867), a French physician, who described his feelings as a patient with gastric cancer and reported that association between cancer and thrombosis; and Rudolf Virchow (1821–1902), a German pathologist, who pioneered the modern concept of pathological processes and identified the three core factors in clot formation such as endothelial injury, venous stasis and hypercoagulability, often referred to as Virchow’s triad. Thrombosis was reported in 1935 as the first occult sign of cancer.
Over 159 years following Armand Trousseau’s death, considerable progress has been made in molecular mechanisms, hemostatic biomarkers, risk assessment models, prevention, and treatment of thrombosis. Currently, numerous assays such as cell-free DNA, miRNA, microparticles, and microvesicles are at our disposal as biomarkers for the measurement of hemostatic system activation. The first manifestation of cancer may be VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE). Arterial thromboembolism (ATE) has recently been established as a significant complication of cancer and may manifest as myocardial infarction, ischemic stroke, including involvement of unusual sites such as renal, mesenteric, adrenal, splanchnic vein thrombosis, and peripheral arterial thrombosis, leading to the burgeoning field of Cardio-oncology. Major acute cardiovascular events after venous thromboembolism have been reported. The study of ATE, VTE, and cancer will entail fundamental basic sciences and clinical trials in understanding more about the biomarkers of hypercoagulability, the role of platelets and platelet microparticles, tumor cell tissue factor and microvesicles, biomarkers of platelet activation, the role of leukocytes, neutrophil extracellular traps, cell-free DNA, risk assessment models, prevention and treatment of VTE in cancer. With the advent of Artificial Intelligence in clinical hemostasis and thrombosis, there is potential for deep learning models to predict cancer-associated thrombosis.
This Special Issue will highlight both the basic and clinical research that advance our understanding of Cancer-Associated Thrombosis, Arterial and Venous Thromboembolism.
I look forward to receiving your contributions.
Dr. Omer Iqbal
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- deep vein thrombosis
- pulmonary embolism
- venous thromboembolism
- anticoagulants
- cardio-oncology
- artificial intelligence
- machine learning
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
